BACKGROUND: ST6GalNAc I is a sialyltransferase controlling the expression of sialyl-Tn antigen (STn), which is overexpressed in several epithelial cancers, including gastric cancer, and is highly correlated with cancer metastasis. However, the functional contribution of ST6GalNAc I to development or progression of gastric cancer remains unclear. In this study, we investigated the effects of suppression of ST6GalNAc I on gastric cancer in vitro and in vivo. METHODS: Gastric cancer cell lines were transfected with ST6GalNAc I siRNA and were examined by cell proliferation, migration, and invasion assays. We also evaluated the effect of ST6GalNAc I siRNA treatment in a peritoneal dissemination mouse model. The differences in mRNA levels of selected signaling molecules were analyzed by polymerase chain reaction (PCR) arrays associated with tumor metastasis in MKN45 cells. The signal transducer and activator of transcription 5b (STAT5b) signaling pathways that reportedly regulate the insulin-like growth factor-1 (IGF-1) were analyzed by Western blot. RESULTS: ST6GalNAc I siRNA inhibited gastric cancer cell growth, migration, and invasion in vitro. Furthermore, intraperitoneal administration of ST6GalNAc I siRNA- liposome significantly inhibited peritoneal dissemination and prolonged the survival of xenograft model mice with peritoneal dissemination of gastric cancer. PCR array confirmed that suppression of ST6GalNAc I caused a significant reduction in expression of IGF-1 mRNA. Decreased IGF-1 expression in MKN45 cells treated with ST6GalNAc I siRNA was accompanied by reduced phosphorylation of STAT5b. CONCLUSION: ST6GalNAc I may regulate the gene expression of IGF-1 through STAT5b activation in gastric cancer cells and may be a potential target for treatment of metastasizing gastric cancer.
BACKGROUND:ST6GalNAc I is a sialyltransferase controlling the expression of sialyl-Tn antigen (STn), which is overexpressed in several epithelial cancers, including gastric cancer, and is highly correlated with cancer metastasis. However, the functional contribution of ST6GalNAc I to development or progression of gastric cancer remains unclear. In this study, we investigated the effects of suppression of ST6GalNAc I on gastric cancer in vitro and in vivo. METHODS:Gastric cancer cell lines were transfected with ST6GalNAc I siRNA and were examined by cell proliferation, migration, and invasion assays. We also evaluated the effect of ST6GalNAc I siRNA treatment in a peritoneal dissemination mouse model. The differences in mRNA levels of selected signaling molecules were analyzed by polymerase chain reaction (PCR) arrays associated with tumor metastasis in MKN45 cells. The signal transducer and activator of transcription 5b (STAT5b) signaling pathways that reportedly regulate the insulin-like growth factor-1 (IGF-1) were analyzed by Western blot. RESULTS:ST6GalNAc I siRNA inhibited gastric cancer cell growth, migration, and invasion in vitro. Furthermore, intraperitoneal administration of ST6GalNAc I siRNA- liposome significantly inhibited peritoneal dissemination and prolonged the survival of xenograft model mice with peritoneal dissemination of gastric cancer. PCR array confirmed that suppression of ST6GalNAc I caused a significant reduction in expression of IGF-1 mRNA. Decreased IGF-1 expression in MKN45 cells treated with ST6GalNAc I siRNA was accompanied by reduced phosphorylation of STAT5b. CONCLUSION:ST6GalNAc I may regulate the gene expression of IGF-1 through STAT5b activation in gastric cancer cells and may be a potential target for treatment of metastasizing gastric cancer.
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Christian Moser; Petra Ruemmele; Sebastian Gehmert; Hedwig Schenk; Marina P Kreutz; Maria E Mycielska; Christina Hackl; Alexander Kroemer; Andreas A Schnitzbauer; Oliver Stoeltzing; Hans J Schlitt; Edward K Geissler; Sven A Lang Journal: Neoplasia Date: 2012-10 Impact factor: 5.715
Authors: Zoe Raglow; Mary Kathryn McKenna; Challice L Bonifant; Wenjing Wang; Marina Pasca di Magliano; Johannes Stadlmann; Josef M Penninger; Richard D Cummings; Malcolm K Brenner; David M Markovitz Journal: Mol Ther Date: 2022-07-12 Impact factor: 12.910
Authors: Avery D Posey; Robert D Schwab; Alina C Boesteanu; Catharina Steentoft; Ulla Mandel; Boris Engels; Jennifer D Stone; Thomas D Madsen; Karin Schreiber; Kathleen M Haines; Alexandria P Cogdill; Taylor J Chen; Decheng Song; John Scholler; David M Kranz; Michael D Feldman; Regina Young; Brian Keith; Hans Schreiber; Henrik Clausen; Laura A Johnson; Carl H June Journal: Immunity Date: 2016-06-21 Impact factor: 31.745
Authors: Kristin E Haugstad; Soosan Hadjialirezaei; Bjørn T Stokke; C Fred Brewer; Thomas A Gerken; Joy Burchell; Gianfranco Picco; Marit Sletmoen Journal: Glycobiology Date: 2016-06-09 Impact factor: 4.313